| Bayer, Onyx to present data at oncology conference | Posted on 16/05/2008 in Pharmaceutical Company Product News Bayer Healthcare and Onyx Pharmaceuticals will present a large body of research data about a potential new drug, Nexavar, to delegates at the 2008 American Society of Clinical Oncology annual meeting.
Their drug, also known as sorafenib, had the potential to treat patients with multiple tumours, either as a single agent or in combination with other drugs.
Henry Fuchs, executive vice-president and chief medical officer of Onyx Pharmaceuticals, said the data would demonstrate Nexavar's proved efficacy and tolerability in liver cancer and advanced kidney cancer.
He added that it would also give "new insight" into its potential as a treatment for other kinds of cancer.
Bayer vice-president of therapeutic oncology Susan Kelley said: "We continue to identify important new areas where Nexavar may provide clinical benefit for people affected by cancer."
The drug is currently available to kidney cancer patients via a study in the US and the companies hope this will be extended to other countries shortly.Other news stories from 16/05/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
